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Testosterone has rapid nongenomic vasodilator eﬀects which could be involved in protective cardiovascular actions. Several
authors suggested speciﬁc mechanisms to explain this eﬀect, but this matter was not clariﬁed yet. We studied the actions of
testosterone and cholesterol on endothelium-denuded rat aorta and their eﬀects on the L-type Ca
2+ current (ICa,L) and potassium
current (IK). Testosterone (1–100μM) totally relaxed, in a rapid and concentration-dependent way, the aortic rings contracted
by KCl or by (−)-Bay K8644 (BAY). Cholesterol also fully relaxed the contractions induced by KCl. None of the potassium
channel antagonists tested (glibenclamide, tetraethylammonium and 4-aminopyridine) modiﬁed signiﬁcantly the relaxant eﬀect
of testosterone. The antagonist of classic testosterone receptors, ﬂutamide, did not modify the vasorelaxant eﬀect of testosterone.
Furthermore, testosterone and cholesterol inhibited either basal and BAY-stimulated ICa,L in A7r5 cells and they have no eﬀects
on IK. In summary, our results demonstrate that cholesterol and testosterone relax rat aorta by inhibiting LTCC. This eﬀect of
testosterone is not mediated by the classic hormone receptor or by potassium channel activation. These results suggest that the
vasodilator mechanism of cholesterol and testosterone is the same.
1.Introduction
Gender diﬀerences in the incidence of cardiovascular health
problems were attributed to diﬀerent sex hormonal patterns
found in women and men. Some studies and clinical
trials suggested a direct modulation of vascular function
by both female and male sex hormones [1]. Testosterone
was associated with negative eﬀects on the cardiovascular
system, such as increased cardiovascular disease risk, throm-
bosis, cardiac hypertrophy, and suspected proatherogenic
eﬀects [2, 3]. However, more recent studies illustrated that
testosterone has some beneﬁcial cardiovascular eﬀects and
several epidemiological studies also indicated that patients
with cardiovascular diseases have low levels of testosterone
[4–7]. On the other hand, high cholesterolemia was related
with the increase in cardiovascular diseases. Some studies
attempting to link hypercholesterolemia with abnormal
vascularsmoothmuscle(SMC)contractionshavefocusedon
the endothelium.
In the last years, vasodilatation induced by testosterone
has been shown in diﬀerent vessels from diﬀerent species
[8, 9]. This vasodilatation is not attenuated by pretreatment
with the classic androgen receptor blocker ﬂutamide [10–
12] and nongenomic testosterone analogues have also been
shown to elicit greater vasodilatation than genomic-acting
analogues [12, 13]. On the other hand, studies performed
with diﬀerent rat vessels showed that removal of the
endothelium slight reduces the testosterone relaxant eﬀect in
aorta [13] and mesenteric artery [11, 14]. However, Yue et al.
(1995) indicated that testosterone induces endothelium-
independent relaxation in isolated coronary artery and
aorta from rabbit [12]. Furthermore, testosterone-induced
relaxation of porcine coronary arteries was associated with
accumulation of cGMP by an endothelium-independent
mechanism [15].
Concerning the testosterone modulation of membrane
ionic ﬂuxes in vascular smooth muscle cells, it was suggested2 Advances in Pharmacological Sciences
that in rat aorta LTCC are inhibited by physiological con-
centrations of this hormone [16, 17], while T-type currents
are only blocked at higher concentrations [17]. On the
otherhand,thefunctionalimplicationofpotassiumchannels
opening in the testosterone-induced vasodilatation of diﬀer-
ent arteries from distinct species has been proposed [10, 11,
18–20].Activationofpotassiumchannelsinvascularsmooth
muscle may induce hyperpolarization of plasma membrane,
which leads to close LTCC and vascular relaxation. Honda et
al. suggested that this mechanism could be more relevant in
situations of systemic hypertension [18].
The eﬀects of cholesterol initially were thought to be
mediated by the endothelium, and some authors sug-
gested that cholesterol decreases the production and/or
the availability of endothelium-derived factors, mainly NO,
leading to endothelial dysfunction and abnormal vascular
reactivity [21]. Recently, it was suggested that cholesterol:
increases vascular sensitivity by increasing Ca2+ permeability
[22], increases calcium sensitization through the Rho-
kinase (ROCK)-mediated pathway [21], inﬂuences vascular
reactivity to endothelin-1 and 5-HT [22, 23], decreases
the expression of LTCC [24], and regulates the expression
levelsofspeciﬁcinwardrectiﬁerandATP-sensitivepotassium
channel subtypes [25]. On the other hand, farnesol, a non-
sterol mevalonate derivative from the cholesterol synthesis
pathway, was reported to inhibit L-type calcium channels
(LTCC) in vascular smooth muscle cells [26, 27] and it
also induces relaxation of contracted rat aortic and human
mesenteric arteries [28].
In summary, testosterone has vascular nongenomic
actions which include vasodilatation, and the eﬀect of
cholesterol at this level is uncertain. The vasodilatation
induced by testosterone could involve the modulation of
several ionic channels. The purpose of this study was to
analyse the eﬀects of testosterone and cholesterol in rat
aorticsmoothmusclecomparingthemechanismsimplicated
in each case. The eﬀect of testosterone and cholesterol on
contracted endothelium-denuded rat aorta was analysed.
The whole cell conﬁguration of the patch-clamp tech-
nique was used to analyse the eﬀects of testosterone and
cholesterol on the calcium and potassium currents in A7r5
cells
2. Methods
2.1. Rat Aorta Contractility Experiments. Male adult Wis-
tar rats (Charles-River, Barcelona, Spain) weighing 400–
500g were housed and acclimatized for at least one week
beforeperformingtheexperimentsinappropriatelaboratory
installations with light cycles of 12 hours light: 12 hours
dark and food and water ad libitum. The rats were used in
accordance with the European regulations about protection
of animals (Directive 86/609) and the Guide for the Care and
Use of Laboratory Animals promulgated by the US National
Institutes of Health (NIH Publication No. 85–23, revised
1996).
The rats were sacriﬁced by decapitation. After thoraco-
tomy, the aortas were obtained, placed in a thermostatized
(37◦C) Krebs modiﬁed solution and the fat and connective
tissue were cleaned. Vascular endothelium was mechanically
removed by gentle rubbing with a cotton bud introduced
through the arterial lumen. The artery rings were placed
in an organ bath (LE01.004, Letica) containing Krebs-
bicarbonate solution at 37◦C continuously gassed with
carbogen. The composition of the Krebs’ modiﬁed solution
was (mM): NaCl 119, KCl 5, CaCl2·2H2O0 . 5 ,M g S O 4·7H2O
1.2, KH2PO4 1.2, NaHCO3 25, EDTA-Na2 0.03, L-(+)-
ascorbic acid 0.6 and glucose 11 (pH 7.4). The rings were
suspended by two parallel stainless steel wires and tension
measurement was performed using isometric transducers
(TRI201, Panlab SA, Spain), ampliﬁer (ML118/D Quad
Bridge, ADInstruments), interface PowerLab/4SP (ML750,
ADInstruments), and computerised system with Chart5
PowerLab software (ADInstruments). During the resting
periods, the organ bath solution was changed every 15
minutes.
Initially, the rings were equilibrated for 60 minutes until
a resting tension of 1.0g. After the equilibration period,
aortic rings were ﬁrstly contracted with high isosmotic KCl
concentrations (60mM) and the absence of endothelium
functionality was conﬁrmed by the lack of relaxant response
to acetylcholine (1μM). After that, the arteries were washed
and allowed to recuperate for at least 45 minutes before
the next induced contraction. The rings were contracted
using KCl (60mM) or (−)-Bay K 8644 (BAY; 0.1μM) and
vasorelaxation induced by testosterone (1–100μM) on these
contractions was analysed.
Aortic rings were contracted with BAY (0.1μM) after
increasing to 10mM the KCl concentration in the Krebs
solution. The Krebs KCl concentration was increased to
10mM to facilitate the opening of Ca2+ channels by Bay
K8644. The eﬀect of cholesterol (1–100 μM) in the artery
rings contracted with KCl (60mM) was also analysed. In
someexperiments,theinvolvementoftheclassicalhormonal
receptors in the vasorelaxant eﬀects of testosterone was
studied using ﬂutamide, a speciﬁc antagonist for the classical
hormonal receptor. In these cases, after contraction, the
arteries were incubated 15 minutes with ﬂutamide (10μM)
and the eﬀect of testosterone in the presence of this
antagonist was analysed. To determine the role of potassium
channels activation in testosterone eﬀects, several potassium
channelinhibitorswereusedinsomeexperiments:tetraethy-
lammonium (TEA; 1mM), an inhibitor of BKCa;g l i b e n -
clamide (10μM), an inhibitor of KATP; and 4-aminopyridine
(4-AP; 1mM), an inhibitor of KV. In these cases, after
contraction, the arteries were incubated 15 minutes with the
potassiumchannelinhibitors andtheeﬀectoftestosteronein
presence of these drugs was analysed. Control experiments
with ethanol, the vehicle used to dissolve the drugs, were
always performed.
2.2. Cell Culture of Vascular Smooth Muscle Cells. The A7r5
cell line, used in this study, is a commercial vascular
smooth muscle cell line obtained from embryonic rata
aorta (Promochem, Spain). The cells were grown in cul-
ture medium Dulbecco’s Modiﬁed Eagle’s Medium/NutrientAdvances in Pharmacological Sciences 3
Mixture F-12 Hams (DMEF-F12; Sigma-Aldrich, Portu-
gal) supplemented with NaHCO3 (1.2g/L), L-ascorbic acid
(20mg/L; Sigma-Aldrich), bovine serum albumin (0.5%;
Sigma-Aldrich), heat-inactivated foetal bovine serum (FBS;
10%; Biochrom), and a mixture of penicillin (100u/mL),
streptomycin (100μg/mL), and amphotericin B (250ng/mL)
(Sigma-Aldrich). The cells were kept in culture at 37◦C
in a humidiﬁed atmosphere with 5% CO2 in air. After
conﬂuence, the cells were placed in culture medium without
FBS (FBS-free culture medium) for 24–48 hours. Trypsiniza-
tion was made using a solution of trypsin (0.3%) in
Ca2+-Mg2+-free phosphate buﬀered solution with EDTA
(0.025%). Subsequently, the cells were kept at 4◦Ci nF B S -
free medium until the realisation of the electrophysiological
experiments.
2.3. Electrophysiological Experiments. The whole cell conﬁg-
uration of patch clamp technique was used to analyse the L-
type calcium current (ICa,L) and the potassium current (IK).
To analyse the ICa,L, the control external solution con-
tained (mM): NaCl 124.0, CaCl2 5.0, HEPES 5.0, tetraethy-
lammonium sodium salt (TEA) 10.0, KCl 4.7 and glucose
6.0, pH 7.4 adjusted with NaOH. Patch electrodes (2–4MΩ)
were ﬁlled with internal solution (mM): CsCl 119.8, CaCl2
0.06, MgCl2 4.0, Na-ATP 3.1, Na-GTP 0.4, EGTA 5.0, HEPES
10.0andTEA10.0,pH7.3adjustedwithCsOH.Thepresence
of Cs+ instead of K+ in the solutions blocked the potassium
currents. The cells were maintained at a holding potential
of –80mV and routinely depolarised every 8s to 0mV test
potential during 500ms to measure ICa,L.
To analyse the IK, the control external solution contained
(mM): NaCl 134.3, CaCl2 1.0, HEPES 5.0, KCl 5.4, and
glucose6.0,pH7.4adjustedwithNaOH.Patchelectrodes(2–
4MΩ) were ﬁlled with internal solution (mM): KCl 125.0,
MgCl2 1.0, Na-ATP 5.0, Na-GTP 0.5, EGTA 0.1, HEPES 20.0,
and glucose 10.0, pH 7.3 adjusted with KOH. For IK analysis,
we used the same holding potential and depolarizations to
60mV for 300 ms were performed every 8s.
Basal ICa,L and IK were measured 3–5 minutes after
patch break to allow the equilibration between pipette and
intracellular solutions. Currents were not compensated for
capacitance and leak currents. All experiments were done
at room temperature (21–25◦C) and the temperature did
n o tv a r yb ym o r et h a n1 ◦Ci nag i v e ne x p e r i m e n t .T h e
cells were voltage clamped using the patch-clamp ampliﬁer
Axopatch 200B (Axon instruments, USA). Currents were
sampled at a frequency of 10kHz and ﬁltered at 0.1kHz
using the analog-digital interface Digidata 1322A (Axon
Instruments, USA) connected to a compatible computer
with the Pclamp8software (Axon Instruments, USA). The
external solution was applied to the cell proximity by
placing the cell at the opening of a 250μm inner diameter
capillary tube ﬂowing at a rate of 20μL/minutes. The
basal and BAY-stimulated (10nM) ICa,L were studied in
the presence of diﬀerent concentrations of testosterone (1–
100μM) and of cholesterol (1–100μM) dissolved in the
external solution.
2.4. Drugs. All drugs and chemicals were purchased
from Sigma-Aldrich Qu´ ımica (Sintra, Portugal), except 4-
aminopyridine that was purchased from Biogen Cientiﬁca
(Madrid, Spain).
Flutamide, (−)-Bay K 8644 (BAY), nifedipine (NIF),
cholesterol, and testosterone were initially dissolved in
ethanol. 4-Aminopyridine (4-AP), glibenclamide, apamin
and tetraethylammonium sodium salt (TEA) were initially
dissolved in deionised water. Appropriate dilutions in Krebs
modiﬁed solution or in the corresponding electrophysiology
external solution were prepared every day before the experi-
ment. Final concentration of ethanol never exceeded 0.1% in
the experiments.
2.5. Statistical Analysis. Statistical treatment of data was
performed using the SigmaStat Statistical Analysis System,
version 1.00 (1992). Results are expressed as mean ± SEM of
n experiments. In the contractility experiments n indicates
the number of rings used, that were obtained from at
least 3 animals. In the electrophysiological experiments n is
the number of cells analysed. Comparison among multiple
groups was analysed by using a one-way ANOVA followed by
Dunnet’s post hoc test to determine signiﬁcant diﬀerences
among the means. Comparison between two groups was
analysed by using Students t-test. Probability levels lower
than 5% were considered signiﬁcant (P<. 05).
In the contractility experiments, the relaxant responses
induced by testosterone and cholesterol are expressed as
a percent of the maximal contraction (Emax=100%) pro-
duced by the corresponding vasoconstrictor agent. In these
experiments, sigmoidal concentration-response curves for
the vasorelaxant eﬀects were ﬁtted and IC50 values (i.e.,
concentrations inducing 50% of relaxation) were estimated
for KCl- or BAY-induced contractions. The antagonist of
classical androgen receptors, ﬂutamide, relaxed by itself the
arteriescontractedbyKCl,andinthiscasethemaximaleﬀect
used to perform the concentration-response curves was the
tension obtained in presence of ﬂutamide.
The ICa,L amplitudes were automatically calculated
between the maximum current peak and the stable current
plateau near the ﬁnal of the every 8s pulse. The ICa,L
variations induced by the diﬀerent drugs used are expressed
as a percent of the basal or BAY-stimulated ICa,L. The IK
variations are expressed as a percent of the basal IK obtained
by depolarization in the absence of any drug.
3. Results
3.1. Vasorelaxant Eﬀects of Testosterone and Cholesterol in
Rat Aorta. The rat aortic rings without endothelium were
contracted by depolarisation with isosmotic KCl (60mM)
solution and by the calcium channel opener BAY (0.1μM).
Maximal contractions elicited by KCl and BAY, 1174.4 ±
27.5mg(n = 54) and 1293.6±77.1mg(n = 18), respectively,
were not signiﬁcantly diﬀerent (P>. 05, Student’s t-test).
These contractile eﬀects were reversible after washing out
with Krebs solution.4 Advances in Pharmacological Sciences
Table 1: IC50 values (μM) of testosterone relaxant eﬀect on rat
aortic rings contracted with BAY and with KCl (60mM) alone or
in the presence of the following drugs: the KV channel blocker 4-
aminopyridine (4-AP; 2mM), the BKCa channel blocker tetraethy-
lammonium (TEA; 1mM), the KATP channel blocker glibenclamide
(GLI; 10μM) and the testosterone receptor antagonists ﬂutamide
(10μM). Each value represents the mean ± SEM from the number
of experiments shown in brackets. ∗P<. 05 versus testosterone IC50
obtained in KCl-contracted arteries, Student’s t-test.
Agents Testosterone IC50 (μM)
BAY 12.94 ± 1.92 (n = 6)∗
KCl 29.88 ± 1.12 (n = 5)
KCl + TEA 23.60 ± 1.06 (n = 4)
KCl + 4-AP 31.24 ± 1.15 (n = 5)
KCl + GLI 27.87 ± 1.21 (n = 3)
KCl + Flutamide 20.67 ± 1.26 (n = 4)
After obtaining stable contraction with KCl and BAY,
the cumulative addition of testosterone (1–100μM) fully
relaxed (100%) in both cases these contractions in a concen-
tration dependent manner (Figure 1(a)). The vasorelaxation
induced by each concentration of testosterone was observed
after 10–15 minutes. The use of testosterone did not injure
the contractility properties of the artery because, after
washing out, a second administration of the contractile
agents elicited a similar contraction than the previous one
(P>. 05, data not shown). The maximal relaxation induced
by testosterone was similar in arteries contracted by KCl or
BAY (Figure 1(a)). However, the IC50 obtained from KCl-
contracted arteries is signiﬁcantly bigger than the obtained
from BAY-contracted arteries (Table 1).
Cholesterol (1–100μM) also induced concentration-
dependent vasorelaxations of the rat aortic rings contracted
byKCl.Themaximalrelaxingeﬀectofcholesterolwassimilar
than the elicited by testosterone (P>. 05) (Figure 1(b)).
However, the IC50 for testosterone (29.88 ± 1.12; n = 5)
was signiﬁcantly bigger than the obtained for cholesterol
(19.10 ±2.58; n = 6) (P<. 05, Student’s t-test).
Ethanol, the vehicle used to dissolve testosterone and
cholesterol, did not have signiﬁcant relaxant eﬀe c ta tt h e
concentrations used (Figure 1).
The vasorelaxant eﬀects of testosterone in rat aorta could
be mediated by the activation of the classical intracellular
receptors. To test this possibility, the eﬀect of ﬂutamide
(10μM) on the testosterone vasorelaxations was analysed.
Initially, after contraction by KCl, the artery rings were
exposed for 15 minutes to ﬂutamide, which caused a
signiﬁcant relaxation on rat aortic rings (54.8 ± 2.7%).
However, ﬂutamide did not aﬀect the vasorelaxant eﬀects of
testosterone, because the IC50 values obtained in the absence
and in the presence of this antagonist were similar (P>. 05,
Student’s t-test; Table 1).
The eﬀects of inhibitors of three diﬀerent potassium
channels (glibenclamide, 4-AP, and TEA) were also investi-
gated in order to analyse the involvement of these channels
in the relaxant mechanism of testosterone. The presence of
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Figure 1: Vasorelaxant eﬀect of testosterone and cholesterol on
rat aorta. (a): Eﬀect of cumulative concentrations of testosterone
(1–100μM) on contractions elicited by KCl (60Mm) and BAY
(0.1μM). (b): Eﬀect of cumulative concentrations of testosterone
and cholesterol (1–100μM) on contractions elicited by KCl
(60mM). Control curve with the eﬀect of the steroids solvent used
(ethanol) is also shown. Each point represents the mean value and
the vertical lines indicate SEM of at least 5 experiments. ∗P<. 05
versus testosterone eﬀect on KCl contractions, Student’s t-test.
glibenclamide, 4-AP or TEA, did not have a signiﬁcant eﬀect
on the contraction induced by KCl (data not show) and did
not modify signiﬁcantly the relaxant eﬀect of testosterone
(Figure 2)( P>. 05, one-way ANOVA with Dunnet’s post
hoc test). The IC50 values calculated for testosterone in the
presenceofanyoneoftheK+ channelinhibitorsdidnotdiﬀer
signiﬁcantly from the IC50 values calculated in the absence of
the blockers (P>. 05; Table 1).Advances in Pharmacological Sciences 5
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Figure 2: Eﬀect of potassium channel inhibitors on rat aorta
relaxation induced by testosterone. Eﬀect of increasing concen-
trations of testosterone (1–100μM) in endothelium-denuded rat
aortic rings contracted with KCl (60mM) in presence or absence
of the potassium channel inhibitors glibenclamide (GLI; 10μM),
4-aminopyridine (4-AP; 1mM), or tetraethylammonium (TEA;
1mM). Each point represents the mean value ± SEM (indicated in
vertical bars) from the number of experiments shown in brackets.
3.2. Eﬀects of Testosterone and Cholesterol on ICa,L in A7r5
Cells. The whole-cell patch clamp technique was used to
analyse calcium current through the LTCC (ICa,L)i nA 7 r 5
cells. The mean value of basal ICa,L density was of 0.93 ±
0.05 pA/pF (n = 91). The application of BAY (10nM; speciﬁc
stimulator of LTCC) signiﬁcantly stimulated the calcium
current on 74.8 ± 5.7% (n = 36) above the basal level. On
the contrary, nifedipine (1μM; LTCC inhibitor) signiﬁcantly
reduced the current until a level of 20.6 ± 2.2% (n = 8)
of the basal current (P<. 05). Even so, the eﬀects of BAY
and/or nifedipine were completely reversible upon washout
of the drug (Figure 3). These results indicate that the current
analysed is a LTCC current (ICa,L). Figure 3 shows the time
course of two experiments in which BAY (10nM) stimulates
basalICa,L (Figure 3(a))andnifedipine(1μM)inhibitedboth
BAY-stimulated and basal (Figures 3(a) and 3(b),r e s p . ) .
Like a proposed vasodilatatory mechanism of testos-
terone is the inhibition of LTCC, we tested the eﬀect of this
steroid on ICa,L. Figure 4(a) shows a typical experiment in
which diﬀerent concentrations (1–100μM) of testosterone
inhibited the basal ICa,L in a reversible way. Figure 5(a)
summarises the results of this type of experiments in
w h i c ht e s t o s t e r o n ea td i ﬀerent concentrations (1, 10, 30 and
100μM) inhibited basal ICa,L in a concentration-dependent
manner. The eﬀect of cholesterol on the basal ICa,L was also
analysed (Figure 5(a)), and like testosterone, cholesterol (1–
100μM) inhibited the basal ICa,L. Furthermore, cholesterol
seems to have similareﬀects that of testosterone on basal ICa,L
(P>. 05, Student’s t-test), even if the testosterone eﬀects are
bigger.
Table 2: Inhibitory eﬀect of testosterone and cholesterol (1–
100μM) on A7r5 cells basal potassium current (IK). Each value
represents the mean of the % of variation of basal IK± SEM from
the number of experiments shown in the brackets.
Concentration Testosterone Cholesterol
1 μM1 .5 ± 1.9% (n = 10) −1.8 ±1.9% (n = 10)
10 μM −0.8 ±2.3% (n = 7) −1.3 ±1.6% (n = 10)
30 μM −1.0 ±1.7% (n = 9) −0.0 ±0.9% (n = 10)
100 μM −6.8 ±3.3% (n = 9) 1.4 ±0.8% (n = 8)
To further characterize the inhibitory eﬀects of testos-
terone on vascular LTCC, we analyse their eﬀect on the
ICa,L stimulated by the LTCC agonist BAY. Figure 4(b) shows
a typical experiment in which diﬀerent concentrations (1–
100μM) of testosterone reversibly inhibited the ICa,L stimu-
lated by BAY (10nM). The inhibitory eﬀect of testosterone
onBAY-stimulatedICa,L wasdependentontheconcentration.
The 100 μM concentration testosterone completely inhibited
thestimulationofBAYreducingtheICa,L belowthebasalICa,L
levels (Figure 5(b)). To further characterize the inhibitory
eﬀects of cholesterol on vascular LTCC, we also analyse
their eﬀect on the ICa,L stimulated by BAY. Cholesterol
inhibited BAY-stimulated ICa,L. The maximal concentration
of cholesterol used inhibited on 73.9 ± 16.8% the BAY-
stimulated ICa,L (Figure 5(b)). Ethanol (0.001–0.1%), the
vehicle used to dissolve testosterone and cholesterol, did not
aﬀect basal or stimulated ICa,L (data not shown). The eﬀect
of testosterone and cholesterol on BAY-stimulated ICa,L is not
signiﬁcantly diﬀerent (P>. 05, Student’s t-test), even if the
cholesterol eﬀects are lower.
3.3. Eﬀects of Testosterone and Cholesterol on IK in A7r5 Cells.
The whole-cell patch clamp technique was used to analyse
potassium current (IK) in A7r5 cells. The mean value of
basal IK density was of 9.1 ± 1.4pA/pF (n = 34). In order
to determine the types of potassium channels that were
responsible for the total current measured, we used selective
blockers of diﬀerent channels. The KV channel blocker 4-AP
reduced basal IK on 35.8 ± 2.9%at+60mV .TEA(1mM),
w h i c hi su s e da saB K Ca channel blocker, reduced net current
by 30.4 ± 5.7% at +60mV (Figure 6). We also tested the
presence of the low-conductance KCa channels using the
selective blocker apamin (10μM), which induced a small
reduction on the basal IK (9.8 ± 2.5%). Glibenclamide,
usually used as a KATP channel blocker, also induced a small
reductionontheIK (8.7±0.8%,n = 5)(Figure 6).Theeﬀects
of the potassium channels blockers used were completely
reversible upon washout of the drug. Thus, our data suggest
that the potassium current measured is mainly constituted
by potassium exit through KV and BKCa channels.
In order to further characterize the vascular relaxant
mechanism of testosterone, the eﬀects of this steroid on
A7r5 IK were analyzed. The results show that diﬀerent
concentrations (1–100μM) of testosterone did not inhibit
the IK current (Table 2). Similar results were observed with
diﬀerent concentrations of cholesterol (Table 2).6 Advances in Pharmacological Sciences
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Figure 3: Eﬀect of nifedipine and BAY on ICa,L amplitude in A7r5 cells. Original records of ICa,L measured in Patch-clamp experiments
showing that: BAY (10nM) stimulates ICa,L and nifedipine (NIF; 1μM) inhibits the BAY stimulation (a); Nifedipine (1μM) directly inhibits
the basal ICa,L (b).
4. Discussion
In the present study, we analyzed the eﬀect of testosterone
and cholesterol on endothelium-denuded rat aorta con-
tracted arteries and on the ICa,L and IK measured by whole
cell voltage-clamp in A7r5 cells.
T h et e s t o s t e r o n er e l a x a n te ﬀect was previously observed
by other authors working with rat aorta [14, 18, 29, 30]
a n do t h e ra r t e r i e ss u c ha sc o r o n a r ya r t e r yf r o md o g s[ 31]
and from humans [32], or human umbilical artery [10].
The vasorelaxant eﬀect of testosterone in rat denuded aortic
rings contracted with KCl was concentration-dependent and
the maximal relaxation eﬀect obtained was 100%, data that
are in agreement with the obtained by Tep-areenan et al.
[14]. Several authors suggested that vasorelaxant eﬀect is
partially dependent of the endothelium [11, 13, 14, 18].
Our data show that, regardless of the endothelium role,
the eﬀect of testosterone is induced in absence of the
endothelium, in agreement with other authors [12, 15, 30,
33]. We show that testosterone fully relaxed the arteries
contracted either by KCl or BAY, although the IC50 was
bigger for KCl contracted arteries. High extracellular KCl
concentrations induce plasma membrane depolarization.
Thisdepolarizationcanactivatevoltage-dependentchannels,
among them LTCCwhose opening increases intracellular
calcium levels and muscle contraction. BAY directly and
speciﬁcally opens LTCC, equally inducing vascular smooth
muscle contraction by intracellular calcium increase. Thus,
these results show that testosterone inhibits KCl- and BAY-
inducedcontractionsandpointtoLTCCinhibitionasacause
of this eﬀect, as previously suggested by other authors [34].
Toconﬁrmthis,weperformedpatchclampstudiesinA7r5to
analyse the testosterone eﬀect on the activity of LTCC. BAY,
a known agonist of this type of channels, clearly stimulates
the basal ICa,L, and nifedipine, a selective antagonist of LTCC,
signiﬁcantly blocked either basal or BAY-stimulated calcium
current. These data conﬁrm that calcium current measured
is due to calcium entry through LTCC. Our results also show
a rapid concentration-dependent inhibitory eﬀect of testos-
terone on basal ICa,L. Other authors suggested previously
that, in A7r5 cells, testosterone inhibits LTCC [16, 17]a n dT -
type calcium channels [17]. Several authors have suggested
that the vasorelaxation induced by androgens in rat aorta
maybeinducedbynonLTCCbecausetherelaxationinduced
by these steroids is minor when contraction is induced by
BAY,thaninKClornoradrenalineinducedcontractions[35].
However, our results show that the contraction induced by
BAY was abolished by testosterone and, for the ﬁrst time,
we showed that testosterone inhibits BAY-stimulated ICa,L,
conﬁrming the inhibitory properties of testosterone on rat
aorta LTCC.
The concentrations of testosterone required to induce
in vitro vasodilatation were supraphysiological. In general,
wide-ranging discrepancies exist between the concentrations
of testosterone required to produce eﬀects in vivo and in
vitro. In general the androgen concentrations needed to
induce a relaxing eﬀect are supraphysiological [8, 12, 35, 36].
Concerning the eﬀects on ionic channels, previous studies
with vascular smooth muscle cells showed discrepancies
in the testosterone concentration needed to observe these
eﬀects. In A7r5 cells, Scragg et al. observed that testosterone
inhibits LTCC and T-type calcium channels at supraphys-
iological concentrations [17]. In the same cells, Hall et
al. observed that nanomolar concentrations of testosterone
inhibit LTCC [16]. In HEK293 cells transfected with the
alpha1C subunit of the human cardiovascular LTCC, it
was shown that concentrations of testosterone from 0.1
to 100μM inhibit these channels [37]. In fresh rat aortic
myocytes, Montano et al. also observed that physiological
concentrations of testosterone inhibit LTCC [36]. As other
lipophilic substances, testosterone is transported by plasmaAdvances in Pharmacological Sciences 7
0
40
80
120
160
200
240
B
a
s
a
l
I
C
a
,
L
a
m
p
l
i
t
u
d
e
(
p
A
)
0 5 10 15 20
Time (min)
TST 1 μM
TST
10 μM
TST
30 μM
TST
100 μM
(a)
0
40
80
120
160
200
240
B
a
s
a
l
l
C
a
,
L
a
m
p
l
i
t
u
d
e
(
p
A
)
0 5 10 15 20 25 30
Time (min)
TST
1 μM
TST
10 μM
TST
30 μM
TST
100 μM
BAY 10 nM
(b)
Figure 4: Eﬀect of testosterone on ICa,L amplitude in A7r5 cells.
Original records of ICa,L measured in Patch-clamp experiments
showing that increasing concentrations of testosterone (TST; 10-
100μM) inhibit basal ICa,L (a) and BAY-stimulated ICa,L (b).
proteins, like the sex hormone binding globulin (SHBG).
The recent identiﬁcation of membrane receptors for SHBG
in some cell types has prompted the suggestion that the
hormone-globulin complex may be able to elicit cellular
responses or that SHBG might be responsible for the
correct orientation of testosterone within the target in cell
membrane [38]. If the SHBG is involved in testosterone
presentation to cell membrane proteins, the absence of this
signalling mechanism in our experiments may contribute to
the marked loss of potency in these studies. Nevertheless,
the elevated concentrations needed seem to be related with
the solubility of the steroids because in our experimental
conditions there are not steroid binding proteins.
The inhibitory eﬀect of testosterone was rapid and
reversible, and this eﬀect disappeared after drug washing.
These data suggest that testosterone eﬀect is mediated by
a nongenomic pathway. Previously, some authors described
the existence of a nongenomic mechanism induced by sex
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Figure 5: Eﬀects of testosterone and cholesterol on ICa,L in A7r5
cells. Diﬀerent concentrations (1–100μM) of testosterone and
cholesterol inhibit basal ICa,L (a) and BAY-stimulated (10nM) ICa,L
(b). Each column represents the mean value ± SEM (indicated in
vertical bars), in percent of the basal (a) or BAY-stimulated (b) ICa,L
from the number of experiments shown in brackets.
steroids which regulates the vascular tone [39]. Besides,
the existence of an unknown receptor, not yet identiﬁed
and placed in the cell surface or in the intracellular space,
was suggested [38, 40]. Also, testosterone could block
LTCC by direct binding to the channels [41]. Moreover,
recently Scragg et al. observed that the LTCC mutation
at the nifedipine binding site results in the loss of the
testosterone vasorelaxation eﬀect [37]. On the other hand,
other authors showed that increase of cyclic nucleotide levels
was associated with the vasodilator eﬀects of testosterone
in porcine coronary myocytes and in rat aortic myocytes8 Advances in Pharmacological Sciences
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[15, 36], suggesting an interaction of testosterone with the
cyclic nucleotide pathway.
In contrast with the hypothesis about calcium channel
inhibition, other investigators reported that the vasodilator
eﬀect of testosterone is due to the stimulation of potassium
channels [13, 18]. The activation of potassium channels
in vascular smooth muscle may induce repolarization and
closing of LTCC, contributing to vascular relaxation. The
bibliographic data about the role of diﬀerent potassium
channelsinthevasorelaxanteﬀectoftestosteronearecontro-
versial. Activation of BKCa channels has been implicated in
the action of testosterone in rat mesenteric arterial bed [11,
19], in porcine coronary myocytes [15], in human internal
mammary artery [20], and in human umbilical artery
[10]. The participation of KV channels in the testosterone
relaxing eﬀect was reported in rat aorta [13], rabbit coronary
arteries [19], and human umbilical artery [10]. Finally,
KATP channel mediates the testosterone vasodilation of rat
aorta [18], human radial artery [42], and human corpus
cavernosum [43]. We used diﬀerent types of potassium
channels inhibitors, to test the involvement of these channels
in the testosterone eﬀect. TEA, glibenclamide, and 4-AP
did not signiﬁcantly modify the vasorelaxant eﬀects of
testosterone suggesting that potassium channel opening is
not involved in the rat aorta vasodilatation induced by
testosterone. To further investigate the eﬀect of testosterone
on potassium channels, we performed patch clamp studies
in A7r5. The current measured was signiﬁcantly inhibited
by the KV channel blocker (4-AP) and by the BKca channel
blocker(TEA),butthelow-conductanceKCa channelblocker
(apamin) and the KATP channel blocker (glibenclamide) only
have a small eﬀect in potassium currents. Thus, our results
showedthatthepotassiumcurrentinA7r5cellsismainlydue
to KV and BKca. On the other hand, our data also show that
testosterone failed to stimulate IK in A7r5 cells, conﬁrming
the contractility data, and demonstrating that potassium
channels are not implicated in the testosterone vasorelaxant
eﬀect in rat aorta. These data agree with those obtained in
pigprostaticsmallarteries[33]andinratthoracicaorta[36].
In fact, the eﬀect of testosterone on potassium channels was
never demonstrated in A7r5 cells.
Several authors have suggested that testosterone-induced
vasodilatation is not attenuated either by pretreatment
with the classic androgen receptor blocker ﬂutamide [10–
12]. Also, polar, nonpermeable testosterone analogues have
been shown to elicit greater vasodilatation than nonpolar,
p e r m e a b l ea n a l o g u e s[ 13]. Besides, testosterone-mediated
vasodilatation is maintained in vessels with androgen recep-
tor deﬁciency [41]. Thus, the eﬀect seems to be independent
of the classical genomic signalling pathway and this eﬀect is
mediated by a diﬀerent signalling pathway or an unknown
receptor. Concerning the rat aorta, some authors observed
that ﬂutamide did not inhibit testosterone-induced vasore-
laxation [12, 14]. Tep-areenan et al. also demonstrate that
mifepristone (an unspeciﬁc steroid receptor antagonist) did
not inhibit the testosterone eﬀect [14]. Our data also show
that the blockage of the intracellular testosterone receptor
did not modify the vasorelaxant action of testosterone,
conﬁrming that the testosterone eﬀect is independent of the
androgen receptor. In contrast, Murphy and Khalil showed
that the testosterone vasorelaxant eﬀect in pig coronary
artery was inhibited by ﬂutamide [44]. On the other hand,
our data show that ﬂutamide elicited an unexpected and
direct relaxation of KCl-contracted arteries. In this sense,
Iliescu et al. have previously shown a vasorelaxation eﬀect
induced by ﬂutamide in rat aorta, and suggested that this
eﬀect is independent of the nuclear receptor activation
and involves activation of the NO-cGMP pathway [45].
Ba et al. also observed this eﬀect in rat arteries and a
bigger ﬂutamide relaxation in arteries from males than from
females, suggesting a sex-dependent mechanism [46].
Severalinvestigatorsobservedthatothersexsteroidshave
the same vasodilator eﬀect than testosterone [47, 48]. Also,
some of the mechanisms proposed to explain the vasodilator
eﬀects of these steroids aresimilar to that proposed for
testosterone, such as inhibition of calcium entry by 17beta-
estradiol and progesterone in pig coronary arteries [48], or
inhibition of LTCC by estrogens in rat aorta [49]. These data
could suggest an unspeciﬁc eﬀect of this group of substances.
In fact, farnesol, a nonsterol mevalonate derivative and
intermediate of the cholesterol synthesis pathway, was also
reported to inhibit LTCC of vascular smooth muscle cells
[26, 27] and also induces relaxation of contracted rat aortic
and human mesenteric arteries [28] .I no r d e rt oi n v e s t i g a t e
the speciﬁcity of the vasodilator eﬀect of testosterone, we
analysed the eﬀect of cholesterol in rat aorta and in A7r5
cells. For the ﬁrst time, we show that cholesterol, like
testosterone, fully relaxed the arteries contracted by KCl,
although the testosterone IC50 was bigger. Regarding the
cholesterol eﬀects on ionic channels, also for the ﬁrst time,
ourresultsshowthatincreasingconcentrationsofcholesterolAdvances in Pharmacological Sciences 9
inhibited basal and the BAY-stimulated ICa,L, indicating a
similareﬀect to that of testosterone on these channels in
rat aorta cells. Also, like testosterone, cholesterol failed to
modify the potassium current measured by patch clamp.
These results suggest that testosterone and cholesterol share
the same mechanism in rat aorta, related with the inhibition
of LTCC.
In summary, our results show that testosterone inhibits
ICa,L in rat aorta vascular smooth muscle cells but not IK.
Also, the eﬀect of testosterone is not mediated by the classic
hormone receptor or by potassium channel activation. In
addition, our results show for the ﬁrst time that cholesterol
has similareﬀects to that testosterone in rat aorta and in A7r5
cells, suggesting a common mechanism of action of both
steroids that could be also shared by other steroids.
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